Clinical trial
Venetoclax, Cladribine Plus Low-dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, Randomized, Controlled Study
NCT05657639 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Soochow University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Venetoclax, Cladribine Plus Low-dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, Randomized, Controlled Study
- Lead sponsor
- The First Affiliated Hospital of Soochow University
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- October 1, 2022
- Completion date
- October 1, 2026
- Enrollment
- 68 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute myeloid leukemia